BELLUS
BELLUS is a Canada-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of refractory chronic cough disorders.
Business Model:
Revenue: $16k
Employees: 11-50
Rankings
Industries / Tags:
Detailed BELLUS Information
BELLUS was acquired by
GlaxoSmithKline.
The acquisition happend on 2023-04-18.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 275 Armand-Frappier Blvd.
City: Laval
State: quebec
Zip: H7V 4A7
Country: CA
Financial Info
Stage:
post ipo equity
Raised Last:
$200M
Raised Total:$372M
Social
Metrics
3,390,167Website Global Rank
4,207Website Monthly Traffic
Twitter Followers
Description
BELLUS is a Canada-based biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of refractory chronic cough disorders.
Contact Phone:
Contact Email:
BELLUS went public on 8/27/2012 on the TMX Group - Toronto Stock Exchange
Listed Exchange:
TMX Group - Toronto Stock Exchange
IPO Date:
8/27/2012
Ticker Symbol:
BLU
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 6/2013 | Thallion Pharmaceuticals | |
| 7/2008 | Innodia |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
